To corroborate the results from MDM2 knockdown experiments, we used a pharmacological inhibitor of the MDM2–p53 interaction, RG7112, the efficacy of which in preclinical models of glioblastoma with its ability to penetrate the blood-brain barrier has been demonstrated [21,22,23]. This evidence concerns the gene MDM2 and glioblastoma.